Recent Research Analysts’ Ratings Updates for Cardinal Health (CAH)

Cardinal Health (NYSE: CAH) has recently received a number of price target changes and ratings updates:

• 3/2/2026 – Cardinal Health had its price target raised by Leerink Partners from $268.00 to $275.00. They now have an “outperform” rating on the stock.
• 2/24/2026 – Cardinal Health had its price target raised by Barclays PLC from $243.00 to $258.00. They now have an “overweight” rating on the stock.
• 2/21/2026 – Cardinal Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 2/12/2026 – Cardinal Health was upgraded by Zacks Research from “hold” to “strong-buy”.
• 2/11/2026 – Cardinal Health had its price target raised by Argus from $232.00 to $248.00. They now have a “buy” rating on the stock.
• 2/11/2026 – Cardinal Health had its price target raised by TD Cowen from $233.00 to $251.00. They now have a “buy” rating on the stock.
• 2/10/2026 – Cardinal Health had its price target raised by Wells Fargo & Company from $237.00 to $256.00. They now have an “overweight” rating on the stock.
• 2/10/2026 – Cardinal Health had its price target raised by JPMorgan Chase & Co. from $209.00 to $243.00. They now have a “neutral” rating on the stock.
• 2/6/2026 – Cardinal Health was given a new $255.00 price target by Morgan Stanley.
• 2/6/2026 – Cardinal Health was given a new $252.00 price target by Robert W. Baird.
• 2/6/2026 – Cardinal Health was given a new $260.00 price target by UBS Group AG. They now have a “buy” rating on the stock.
• 2/6/2026 – Cardinal Health had its price target raised by Mizuho from $222.00 to $235.00. They now have an “outperform” rating on the stock.
• 2/6/2026 – Cardinal Health had its price target raised by Evercore Inc from $250.00 to $260.00.
• 2/5/2026 – Cardinal Health had its “outperform” rating reaffirmed by Evercore Inc. They now have a $260.00 price target on the stock.
• 2/5/2026 – Cardinal Health had its price target raised by Leerink Partners from $240.00 to $268.00. They now have an “outperform” rating on the stock.
• 1/29/2026 – Cardinal Health had its price target raised by Morgan Stanley from $224.00 to $245.00. They now have an “overweight” rating on the stock.
• 1/27/2026 – Cardinal Health had its “buy” rating reaffirmed by TD Cowen.
• 1/23/2026 – Cardinal Health had its price target raised by Argus from $211.00 to $232.00. They now have a “buy” rating on the stock.
• 1/22/2026 – Cardinal Health was upgraded by Argus to “strong-buy”.
• 1/22/2026 – Cardinal Health had its price target raised by Jefferies Financial Group Inc. from $220.00 to $270.00. They now have a “buy” rating on the stock.
• 1/21/2026 – Cardinal Health had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 1/15/2026 – Cardinal Health had its price target raised by Wells Fargo & Company from $221.00 to $237.00. They now have an “overweight” rating on the stock.
• 1/14/2026 – Cardinal Health was given a new $250.00 price target by Robert W. Baird.
• 1/13/2026 – Cardinal Health was given a new $240.00 price target by Leerink Partners.
• 1/12/2026 – Cardinal Health was given a new $222.00 price target by Mizuho.
• 1/9/2026 – Cardinal Health was upgraded by Citigroup Inc. from “neutral” to “buy”. They now have a $244.00 price target on the stock, up from $190.00.

Cardinal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Investors of record on Wednesday, April 1st will be given a $0.5107 dividend. The ex-dividend date of this dividend is Wednesday, April 1st. This represents a $2.04 annualized dividend and a yield of 0.9%. Cardinal Health’s dividend payout ratio (DPR) is presently 29.35%.

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.